Delia Yu
Overview
Explore the profile of Delia Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borja-Tabora C, Fernando L, Lopez Medina E, Reynales H, Rivera L, Saez-Llorens X, et al.
Clin Infect Dis
. 2024 Jul;
80(1):199-206.
PMID: 38995684
Background: Dengue is an increasing threat to global health. This exploratory analysis evaluated the immunogenicity, safety, and vaccine efficacy (VE) of a live-attenuated tetravalent dengue vaccine (TAK-003) in participants enrolled...
2.
Sirivichayakul C, Biswal S, Saez-Llorens X, Lopez-Medina E, Borja-Tabora C, Bravo L, et al.
J Infect Dis
. 2024 Apr;
230(6):e1214-e1225.
PMID: 38682569
Background: We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. Methods: Children 4-16 years of age...
3.
Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al.
Lancet Glob Health
. 2024 Jan;
12(2):e257-e270.
PMID: 38245116
Background: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in...
4.
Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C, et al.
Clin Infect Dis
. 2021 Oct;
75(1):107-117.
PMID: 34606595
Background: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety in...
5.
Lopez-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, et al.
J Infect Dis
. 2020 Dec;
225(9):1521-1532.
PMID: 33319249
Background: Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. Methods: Children (20 099, 4-16 years old) were randomized to receive...
6.
Tricou V, Saez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal A, et al.
Lancet
. 2020 Mar;
395(10234):1434-1443.
PMID: 32197107
Background: An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose...
7.
Biswal S, Borja-Tabora C, Vargas L, Velasquez H, Alera M, Sierra V, et al.
Lancet
. 2020 Mar;
395(10234):1423-1433.
PMID: 32197105
Background: A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to...
8.
Kerdpanich P, Chanthavanich P, Reyes M, Lim J, Yu D, Ama M, et al.
PLoS Negl Trop Dis
. 2018 Jun;
12(6):e0006340.
PMID: 29874228
Background: This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen,...
9.
Saez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal A, et al.
Lancet Infect Dis
. 2017 Nov;
18(2):162-170.
PMID: 29122463
Background: Development of vaccines that are effective against all four dengue virus serotypes (DENV-1-4) in all age groups is important. Here, we present 18-month interim data from an ongoing study...
10.
Saez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, et al.
Lancet Infect Dis
. 2017 Apr;
17(6):615-625.
PMID: 28365225
Background: Dengue is the most common mosquito-borne viral disease in human beings, and vector control has not halted its spread worldwide. A dengue vaccine for individuals aged 9 years and...